NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.53 -0.07 (-0.92 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$7.60
Today's Range$7.35 - $7.75
52-Week Range$4.50 - $9.95
Volume739,100 shs
Average Volume1.33 million shs
Market Capitalization$449.89 million
P/E Ratio-11.58
Dividend YieldN/A
Beta2.11
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in December 2013 and is headquartered in Norwood, MA.

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.44 million
Book Value$1.04 per share

Profitability

Net Income$-32,420,000.00

Miscellaneous

Employees47
Market Cap$449.89 million
OptionableOptionable

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) released its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.05. The biopharmaceutical company had revenue of $1.09 million for the quarter, compared to the consensus estimate of $1.66 million. View Corbus Pharmaceuticals' Earnings History.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Corbus Pharmaceuticals.

What price target have analysts set for CRBP?

6 Wall Street analysts have issued 1 year price objectives for Corbus Pharmaceuticals' stock. Their forecasts range from $22.00 to $38.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $26.20 in the next twelve months. This suggests a possible upside of 247.9% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.

What is the consensus analysts' recommendation for Corbus Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.

Has Corbus Pharmaceuticals been receiving favorable news coverage?

News articles about CRBP stock have trended positive recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days.

Who are some of Corbus Pharmaceuticals' key competitors?

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the folowing people:
  • Yuval Cohen, Chief Executive Officer & Director
  • Mark A. Tepper, President & Chief Scientific Officer
  • Sean F. Moran, CFO & Principal Accounting Officer
  • Barbara White, Chief Medical Officer
  • Robert Discordia, VP-Pharmaceutical Development & Manufacturing

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $7.53.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $449.89 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is http://www.corbuspharma.com.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]


MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  424
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel